Online inquiry

IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2580MR)

This product GTTS-WQ2580MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MPL gene. The antibody can be applied in Chronic immune (idiopathic) thrombocytopenic purpurea (ITP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005373.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4352
UniProt ID P40238
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2580MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3143MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ13292MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ3498MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ2209MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ3414MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aALB03
GTTS-WQ13469MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ10219MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ4442MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW